LYT-310

LYT-310 is an oral prodrug formulation of cannabidiol (CBD) developed using PureTech Health's proprietary Glyph technology platform. This technology enhances the oral bioavailability of CBD by targeting lymphatic transport, resulting in a three to fourfold increase in systemic exposure compared to unmodified CBD in preclinical models. The improved pharmacokinetic profile aims to expand the therapeutic potential of CBD for a broader range of neurological and central nervous system disorders, including both rare and common forms of epilepsy, as well as other conditions where higher doses are required for efficacy. LYT-310 is designed to enable more effective oral administration, potentially reduce gastrointestinal and liver side effects associated with current CBD formulations, and provide a scalable product suitable for adolescents and adults[5][6][7].